超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

億騰醫藥  Eddingpharm
億騰成立于2001年，作為中國領先的專業醫藥公司，我們長期以來一直致力于將全球優質的藥品帶入中國醫療市場，提供給病患更多的治療及康復機會，促進中國臨床專家和全球領先醫學研究機構的合作和交流，為中國臨床醫生提供學術支持。

公司自2001年成立以來，發展至2011年底，在國內雇員已超過700名，主要從事藥品的經銷和推廣、產品注冊以及臨床試驗的管理等業務。

公司于2012年3月在美國成立Eddingpharm (U.S.) Company,并在洛杉磯組建了具備研發背景的產品發展團隊，主要從事與全球領先的研發機構的協調和溝通，尋求將處于臨床前或臨床試驗階段的創新專利藥物引進中國市場的機會。

公司聚焦于臨床營養、抗腫瘤治療、抗感染治療、呼吸系統疾病治療等領域的產品發展以及醫學推廣。

我們力爭通過和跨國醫藥公司、海外專業醫藥公司、全球領先研發機構等合作，以專利授權引進、成立合資公司、建立戰略聯盟、獨家經銷等形式建立聚焦于上述四個主要治療領域的產品組合。

目前億騰已與多家跨國醫藥公司和海外專業醫藥公司建立起長期合作的關系，在上述四個治療領域建立了富有市場競爭優勢的產品組合以及產品線；同時億騰還在積極發展與全球領先研發機構合作,授權引進創新藥物的中國市場權利。

經過多年的努力，至2011年年底億騰的市場學術推廣人員發展超過600名，針對中國市場已形成一套高度整合與管理良好的市場營銷系統，醫學推廣覆蓋至全國大部分主要城市，同年12月底我們經銷的產品或醫學推廣代表覆蓋至超過2900家醫院。

Eddingpharm was founded in 2001. As China’s leading pharmaceuticals marketing company, Eddingpharm has been committed to bring in high quality medicines from all over  the world to the Chinese market, to provide patients more treatment options and better opportunity of recovery.  We promote the cooperation and exchanges between Chinese clinical experts and the leading international medical research institutions. We provide academic support to Chinese clinical doctors.

Since its inception in 2001, the company has grown into an organization of more than 700 employees in China by the end of  2012. The company focuses on product sales and marketing, product registration,  and clinical trials management.

In March, 2012, Eddingpharm established Eddingpharm (U.S.) Company in USA, and set up a business development team with strong research and development background. The team is engaged in coordination and communication with the world’s leading research and development institutions and biotech companies. It is actively seeking the opportunity to introduce innovative proprietary medicines in pre-clinical or clinical development phase into the Chinese market.

The company is engaged in the product development and sales and marketing in four core therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory-system.
 

We strive to create a portfolio of products focused on the above mentioned four major therapeutic areas, through strategic alliance, including exclusive distribution, product in-licensing, and joint-venture, with world’s leading pharmaceutical companies, overseas specialized pharmaceutical companies, and global leading research and development focused biotech companies.
 

Eddingpharm has established long-term cooperative relationship with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. At the same time, Eddingpharm is actively developing cooperation with the leading global biotech companies and research and development institutions to gain the regional rights of innovative medicines and to introduce them to the China market.
 

Through years effort, Eddingpharm has assembled  a team of nearlysales and marketing professionals and established a highly integrated and well-managed sales network covering most of the major cities across the country. By December 2012, our products and our sales and marketing professionals have covered more than 3000 hospitals.